Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
27 hedge funds and large institutions have $4.02M invested in Regulus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0.12% less ownership
Funds ownership: 2.3% → 2.18% (-0.12%)
7% less capital invested
Capital invested by funds: $4.32M → $4.02M (-$301K)
21% less funds holding
Funds holding: 34 → 27 (-7)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$1.16M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$71.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$32.7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$201K |
| 2 |
VF
Virtu Financial
New York
|
-$57K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$44K |
| 4 |
SG Americas Securities
New York
|
-$24K |
| 5 |
Jane Street
New York
|
-$14K |
RGLS Hedge Fund Activity: Q3 2020 in Review
27 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2020, worth a combined $4.02M — down 7% from $4.32M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RGLS and 2 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was BVF Inc, adding an estimated $1.16M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $201K sold.
- 27 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2020, down from 34 in Q2 2020.
- Funds reported $4.02M of Regulus Therapeutics stock for Q3 2020, down 7% quarter-over-quarter.
- 2 funds opened new Regulus Therapeutics positions in Q3 2020 and 9 closed out, a net change of -7 holders.
- The largest Regulus Therapeutics buyer in Q3 2020 was BVF Inc, an estimated $1.16M added.
- The largest Regulus Therapeutics seller in Q3 2020 was Renaissance Technologies, an estimated $201K sold.
Based on aggregated 13F filings for Q3 2020.